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Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
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CHAPTER  1 
1.1 Parkinson’sdisease
Parkinson’s disease (PD) was first described in 1817 by the English physician named
JamesParkinson.He called it ‘shakingpalsy’with trembling andmuscleweakness as
themost important symptoms.HisEssayon theShakingPalsywasbasedononly six
individuals 1. Four decades later JeanMartin Charcot added rigidity to Parkinson’s
clinicaldescriptionandattachedthenameParkinson’sdiseasetothesyndrome.
PD is the most common movement disorder and the second most common
neurodegenerativedisorderafterAlzheimer’sdisease.TheestimatedprevalenceofPD
is12%ofthepopulationover65years.Thisfigureincreasesto35%inpeople85years








The symptoms of PD are caused by a slow but progressive loss of neurons in the
substantia nigra pars compacta accompanied by the presence of intraneuronal Lewy
bodies. Braak and colleagues (2004) proposed a staging procedure of PD pathology.
This staging procedure suggests a premotor period in which typical pathological
changes,LewyneuritisandLewybodiesspreadfromtheolfactorybulbandvagusnerve
to lower brainstem regions (stages 1 to 2), followed by a symptomatic periodwhen
pathological changes involve the midbrain including substantia nigra (stage 3),
mesocortex (stage 4), and eventually neocortex (stages 5 to 6) 5. Positron emission
tomography(PET)andsinglephotonemissioncomputedtomography(SPECT)imaging
in vivo confirmed the loss not only of the brainstem dopaminergic system, in
agreement with the severity of motor parkinsonism, but also of the serotonergic,
noradrenergic, and cholinergic neurotransmitter systems, correlatingwith PDrelated
nonmotorsymptoms6,7,8.
1.2 PsychopathologyinParkinson’sdisease
In the past decade, it has becomemore andmore recognized that in PD nonmotor
symptomssometimesprecedemotorsymptomsandthatthesesymptomssignificantly
contributetodisability,reducedqualityoflifeandcaregiverdistress913.Almost90%of
all PD patients experience nonmotor symptoms during the course of the disease 14.
Nonmotor symptomsmay includemood disorders, cognitive deficits, hallucinations,
olfactorydisturbances,fatigue,pain,sleepdisorders,andautonomicdysfunction.
 9
MOOD & MOT IVAT ION  I N  P ARK INSON ’ S  D I S EAS E 
This chapter focuseson thepsychopathological symptoms in PD: depression, apathy,





Prevalence rates of psychopathology in PD vary widely due to different assessment
methods,selectionofthepopulationstudied,typeofdisorder includedandstatistical
methodused.FordepressivesyndromesinPD,theprevalenceratesvarybetween2.7%
and 90%. The lowest prevalence rates are reported in population studies, whereas
studies in outpatient and inpatient settings tend to report higher prevalence
rates10,15,16.
The prevalence ofapathy in outpatient samples is reported to range from 16.5% to
51%1719.Inacommunitybasedstudyof232PDpatients,theprevalenceofapathywas
38%. In 11% of the total sample apathy coexisted with depression and dementia,
whereas10%hadapathyanddepression,and6.5%apathyanddementia20.
Foranxiety,itisestimatedthatupto40%ofPDpatientsexperiencesubstantialanxiety.







The cumulative prevalence is very high; at least 75% of PD patientswho survive for
morethan10yearswilldevelopdementia25.
Hallucinations also belong to the most frequently observed psychopathological









in PD. Aworkgroup from theNational Institute forNeurological Diseases and Stroke
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andtheNationalInstituteofMentalHealth(NINDS/NIMH)recommendedthataninclu
siveapproachshouldbeusedbydiagnosingdepressioninPD.Thismeansallsymptoms
shouldbeconsideredas related todepression, regardlessof theiroverlapwithPDor
othermedicalconditions29.
Symptoms of apathy and depression are closely related and sometimes difficult to
recognize or distinguish from each other in PD patients. The concept of apathy as a
syndrome in itself and not as a symptom of depression, has gainedmore attention.
Onlyrecently,diagnosticcriteriahavebeenproposedforapathy30.Mulinetal.(2010)
validatedthesecriteriainapopulationofdifferentneuropsychiatricdiseases31.
Anxiety is most commonly diagnosed by the diagnostic criteria of the DSM IV 21.
A differentiation between nonepisodic (generalized anxiety disorder, agoraphobia,
socialphobia)andepisodic(panicdisorder)anxietydisordercanbemade.Thecomor
bidityofanxietyanddepression inPD ishighandtheapplicationof theDSManxiety
criteria in PD has the same difficulties of symptomatic overlap. Also shortlasting
anxiety episodes related to motor fluctuations do not fulfill criteria for any specific
DSMIVanxietydisorder32.
In2007,aTaskForceoftheMovementDisorderSociety(MDS)definedclinicaldiagnos
tic criteria for probable and possible PDdementia (PDD) and practical guidelines to
establish the diagnosis and characterize the disorder. Core features, which must be
met, include the diagnosis of PD according to Queen Square Brain Bank criteria, PD








for screening or assessment of severity of psychopathological symptoms in PD.MDS
taskforceshavereviewedratingscalesfordepression,apathy,anxiety,andhallucina
tions in PD and reported evaluations and recommendations. The most appropriate
scaleisdependentontheclinicalorresearchgoal32,3638.
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Pathophysiology
Studies addressing the pathophysiology of psychopathological symptoms in PD have
shifted attention from the dopaminergic neurotransmitter system to other neuro
transmitter systems. The pathophysiology of depression, apathy, anxiety, PDD, and





disease as well as variability in the clinical expression of motor and nonmotor
symptoms. Previous studies addressing different subtypes of PD patients focused












problem in diagnosing depression in PD is the considerable overlap in symptoms of
depressionand symptomsofPD.An ‘inclusive’ approachhasbeenadoptedbywhich




Another diagnostic issue comprises the overlap between depression and apathy. On
theonehand,depressivepatientsoftenhaveapatheticsymptoms;apathymaythere
forebeoneoftheclinicalsignsofdepression.Ontheotherhand,apathycanalsobe
seenasacore featureofPDand recent studieshavesupport thenotion thatapathy
can be discerned from depression 18, 44, 45. Recently, diagnostic criteria for apathy in
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neuropsychiatric disorders have been proposed, but these criteria need thorough
















Chapter2provides a systematic reviewofprevalence studiesofdepression inPD. In





Chapter 3 is concernedwith the influence of somatic symptoms in depression rating
scales on the diagnosis and assessment of depression in PD. The recognition and
assessmentofdepression inPDpatients isoftendifficultdue tooverlapbetweenPD
anddepressivesymptoms.Currentlyaninclusiveapproachisadopted,whichincorpo
ratesthatadjustedcutoffscoresneedtobeusedforPDpatients.Anotherapproach
could be to adjust the depression rating scales, excluding the somatic items. We
investigatedtheinfluenceofsomaticsymptomsontheclinimetricperformanceoftwo
commonly used depression rating scales; the Hamilton Depression Rating Scale and
MontgomeryÅsbergDepressionRatingScale.
Chapter 4 describes a cluster analysis performedwithmotor and psychopathological
symptoms that aims at identifying subtypes of PD not only on the basis of motor
symptoms, but on the basis of psychopathological and motor symptoms. Different
subtypesofmotorsymptomsinPDhavebeendescribedandithasbeensuggestedthat
the variousmotor presentations of PD are also characterized by a different risk and
severity of specific neuropsychiatric symptoms. The question is can we establish
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homogeneous subtypes of PD patients on the basis of both motor and
psychopathologicalsymptoms.
Chapter 5 describes a validation study of proposed diagnostic criteria of apathy in a
populationofPDpatients.Researchandclinicalpracticehavebeenhamperedbyalack
ofgenerallyaccepteddiagnosticcriteria.Aconsensusmeetingofexpertshasrecently




Involvement of the prefrontalbasal ganglia system has been hypothesized. We
investigatedthestructuralcorrelatesbycorrelatingthelevelofapathywithanatomical
changesingreymatterdensity,derivedfrommagneticresonanceimagingscans.
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settings anddifferentdiagnostic approachesof studies.UsingMedlineonPubmed,a
systematic literature searchwas carried out for studies of depression in Parkinson’s
disease.Atotalof104articleswere includedandassessedforquality;51articlesful





structured interview to establish DSM criteria, the reported prevalence of major
depressivedisorderwas19%,whileinstudiesusingDSMcriteriawithoutastructured
interview, the reported prevalence ofmajor depressive disorderwas 7%. Population
studies report lower prevalence rates for both major depressive disorder and the
clinicallysignificantdepressivesymptomsthanstudiesinothersettings.Thissystematic
review suggests that the average prevalence of major depressive disorder in PD is
substantial,butlowerthangenerallyassumed.
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2.1 Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by tremor,
bradykinesia, rigidity, and postural instability. In addition, a high prevalence of
psychopathologic syndromes is reported, including affective disorders, cognitive
deterioration,andperceptualandbehaviouralsymptoms.Depressionisknowntohave
amajor impacton theprognosisofPD:depressedPDpatients score loweron scales
assessing motor function and activities of daily living (ADL), exhibit more cognitive
symptoms, and report a lower quality of life 13. Despite this, depression in PD is
underdiagnosedandundertreated4,5.
PrevalenceratesofdepressivesyndromesinPDthatarereportedintheliteraturevary




bidity ingeneral, the lowestprevalencesare reported inpopulationstudies,whereas
studies in outpatient and inpatient settings tend to report higher prevalence rates.
Studiesmeasuringdepressivesymptomsonaratingscalemayyieldhigherprevalences
than studies using diagnostic criteria for depression, such as those of the Diagnostic
and Statistical Manual for mental disorders (DSM) of the American Psychiatric
Association (APA) or the International Classification of Diseases (ICD) of the World
Health Organisation (WHO) 9, 10. Studies using a structuredor semistructured inter
viewprobablyyield themostconservativeestimates 11.Even ifdiagnosticcriteriaare




depressive disorder only, or less severe syndromes such as dysthymia and minor
depression.Finally:somestudiesusepointprevalences,whereasothersusemonthly
prevalences,whichmaygiverisetodifferentprevalencerates.
All these factorsmake it difficult toestimate theextent towhichdepression compli
cates PD. The aim of this systematic review is to calculate average prevalences of
depressive disorders taking the different settings and the different approaches to
diagnosisofstudiesintoaccount.
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2.2 Methods
Searchstrategy
A systematic literature searchwas carried out inMedline using Pubmed. The entire
timescalewasuseduptoFebruary2007(included).Thefollowingkeywordswereused




identified from the reference lists of the selected articles as well as from previous
review studies. Articles in languages other than English,German, French, andDutch,
wereexcluded(5).Atotalof165articleswerereadinfull.Afterreadingthesearticles,
another 61 articles were excluded because of the following reasons: there was no
referencetotheprevalenceofdepression(49),patientswithdepressionwereexcluded
(5), the population did not include PD patients (2), depression was only related to







(AL) who made a final decision. The quality assessment used criteria adapted from
Aarslandetal.asshowninTable113.Inordertoensureaminimumqualityofstudies
includedinthereview,onlystudiesthatscoredatleastonepointonallthreecriteria:
case identification, diagnostic criteria for PD, and diagnostic criteria for depression,
wereincluded.ThefulllistofassessedstudiesisgiveninReijnders,Ehrt,etal.(2008).
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Table1. QualityassessmentcriteriaasadaptedfromAarslandetal.(2005)13
  Studiesarescoredfrom0to3inthreedifferentdomains,yieldingamaximumscoreof9















































rates. The authors therefore contacted the first author of those studies to check
whethertheywereindeedbasedonthesamesample.Inallbutonecasetheauthors
received an answer. They decided to follow the following strategy: if studies were
basedonthesamesample,onlythefirstpublicationwasincludedinthemetaanalysis.
Ifforsomereason,studiesbasedonthesamesamplehadvaryingnumbersofpatients
included, the study with the highest number of patients was included. For studies
based on cumulative databases, only the most recent publication with the highest
number of patients was included. Some publications were based on joint databases
from within a single or between several research groups and in this case only the
publicationstemmingfromthecombineddatabasewasincludedinthemetaanalysis.
Thesetof studies thatwe receivedno informationonwerepresumed tocome from
thesamedatabase.
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Statistics
Data are presented as numbers and proportions. Descriptive data are presented as
mean with 95% confidence intervals (95% CI). For studies that assessed specific
depressive disorders, the prevalences were recorded. In addition, the percentage of
patients with ‘clinically relevant depressive symptoms’ was scored. For studies that
assessedbothoneormore depressivedisorders either separately, or combined, this
percentage equals the combined prevalences of all depressive disorders. For studies
using cutoff scores on rating scales, where no DSM diagnoses are available, this
percentage represents the presence of depressive symptoms in a clinically relevant
severity,asreflectedbythenumberofpatientsscoringabovethesetcutoffwastaken
asthe‘overallprevalenceofdepression’.








tionbased studies, 3 studies in general practices,71 studies inoutpatient settings,5
studiesinhospitalinpatientsettings,and2studiesinnursinghomes.Another7studies
used patients from a combination of different settings: population and outpatient
samples (4), outpatient and inpatient samples (2), and outpatient and nursing home
samples(1).Insomeofthestudiesinoutpatientsettings,thepopulationwasrestricted
to a specific subgroup: patients screened for possible DBSscreening (3), patients on
longtermlevodopatreatment(3),denovopatients(3),andpatientswithconcurrent
dementia(1).Differentdiagnosticcriteriafordepressionwereused:31studiesuseda




maximum score for quality according to these criteria is 9. The actual scores ranged
from1 to 7,with ameanof 3.77 (SD: 1.73). The quality of depression studies in PD










The prevalences of major depressive disorder, minor depression, and dysthymia, as
wellasclinicallysignificantdepressivesymptomsareshowninTables2A,2B,and2C.
Overall,majordepressivedisorderwaspresentin17%ofpatients,minordepressionin
22%, and dysthymia in 13%. The prevalence of clinically significant depressive
symptoms was 35%. While dysthymia may be diagnosed in the presence of major
depressive disorder or minor depression (the concept of ‘double depression’), it is
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Table2A. Reportedprevalences(%)ofmajordepressivedisorder,minordepression,dysthymia,and
  clinicallyrelevantdepressivesymptoms(Structuredclinicalinterview)













      
Starkstein(1990)17 Outpatientclinic 105 5 21 20  41
Starkstein(1992)18 Outpatientclinic 92 5 20 21  41




33 6 30  27 57
Liu(1997)20 Outpatientclinic 109 5 16.5  25.7 42.2
DeRijk(1998)21 Population 384 5 2.3  4.7 7.0
Starkstein(1998)22 Outpatientclinic 112 6 22  31.3 53.3
Leentjens(2000)23 Outpatientclinic 63 6 25   25
Leentjens(2000)24 Outpatientclinic 53 6 23   23
Anguenot(2002)25 Outpatientclinic 135 6 55.6  2.2 57.8
Naarding(2002)26 Outpatientclinic 85 6 23.5   23.5
Weintraub(2003)5 Outpatientclinic 77 6 20.8 13  33.8
Lauterbach(2004)27 Outpatientclinic 28 5 14.3  3.6 17.9
Nuti(2004)28 Outpatientclinic 90 6 21.1  18.8 39.9
Ertan(2005)29 Outpatientclinic 109 6 22.9 28.4  51.4
Papapetropoulos(2005)30 Brainbankdata 67 7    43.3
Costa(2006)31 Inpatientclinic 58 5 20.7 34.5  55.2
Costa(2006)32 Inpatientclinic 83 6 21.7 25.3  47
Visser(2006)33 Outpatientclinic 92 6 19   19
Wichowicz(2006)34 Population 100 6 35   35

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Table2B. Reportedprevalences(%)ofmajordepressivedisorder,minordepression,dysthymia,and
  clinicallyrelevantdepressivesymptoms(Clinicalinterview)



















339 4    47
Brown(1990)37 Outpatientclinic 40 6    25
Aarsland(1996)38 Population 235 6 7.7   7.7
Tandberg(1996)39 Population 245 6 7.7   7.7
Tandberg(1997)40 Population 245 6 7.7   7.7
Tandberg(1998)41 Population 239 6 7.8   7.8
Aarsland(1999)42 Population 235 5 7.2   7.2
Karlsen(1999)3 Population 233 6 7.7   7.7
Cubo(2000)43 Outpatientclinic 88 5 7.3   7.3
Giladi(2000)44 Outpatientclinic 172 5    33
Larsen(2000)45 Population 240 6 7.6   7.6
Krishnan(2003)46 Outpatientclinic 126 5    12.7

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Table2C. Reportedprevalences(%)ofmajordepressivedisorder,minordepression,dysthymia,and
  clinicallyrelevantdepressivesymptoms(Ratingscale)



















60 6    32.7
Meara(1999)49 GeneralPractice 132 5    64
Schrag(2000)1 GeneralPractice 92 5    19.6
Happe(2001)50 Outpatientclinic 56 4    76.4
Schrag(2001)51 GeneralPractice 97 5    19.6
Shulman(2001)52 Outpatientclinic 99 3    36
Happe(2002)53 Outpatientclinic 116 4    37.1
Marinus(2002)54 Outpatientclinic 177 4    38.4
Schrag(2002)55 GeneralPractice 128 5    20
Shulman(2002)4 Outpatientclinic 101 3    44
Rojo(2003)56 Outpatientclinic 353 4    56.9
Hely(2005)57 Outpatientclinic 52 4    53.6
Holroyd(2005)58 Outpatientclinic 100 4    15
Kang(2005)59 Population 193 5    13
Prado(2005)60 Outpatientclinic 60 4    38.3
KirschDarrow(2006)61 Outpatientclinic 80 3    26.3
Weintraub(2006)62 Outpatientclinic 130 4    36.2







report significantly lower prevalences than studies in respectively general practices,
outpatientsettings,inpatientsettings,andnursinghomes(2=143.5,df=1,p<0.001;
2=288.6,df=1,p<0.001;2=335.6,df=1,andp<0.001;2=27.2,df=1,p<0.001










Population Numberofstudies Prevalence Numberofstudies Prevalence
Generalpopulation 10 7.8 11 8.9
GeneralPractice 0  4 32.8
Outpatientsetting 16 21.7 31 38.5
Inpatientsetting 2 21.3 4 54.4
Nursinghome 0  1 32.7

The reported prevalence of major depressive disorder in studies using a (semi)
structuredinterviewtoestablishDSMcriteriarangesfrom2.3to55.6%withaweighted








This is the firstextensive reviewof theprevalenceofdepressivedisorders inPD that
takes the different settings and diagnostic approaches of the various studies into
account. It shows that the average prevalence ofmajor depressive disorder in PD is
17%,which is substantial,but less than theprevalence rates thatareusuallyquoted.
Minor depression was present in 22% and dysthymia in 13% of PD patients. In PD
patients in thegeneralpopulation thesenumbersare lower,while theyarehigher in
hospital out and inpatients settings. We could not confirm that the prevalence of






a quality assessment before including studies. In the study by Slaughter et al., that
included45studies,thesettingwasnotconsidered.Reportedaverageprevalencesof
the 11 included studies that used diagnostic criteria were significantly higher than
thoseofourreview:25%formajordepressivedisorder,37%forminordepression,and
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23% for dysthymia 14. Clinically significant depression was present in 42% of PD
patients.Thediscrepancywithourfindingsisprobablyduetothefactthatsevenofthe
elevenstudiesincludedinthereview,werenotincludedinouranalysisbecauseofan
insufficient quality rating. Veazey et al. reviewed 16 studies and gave a range for





from7.3% to32%. It is not clear to theauthorshowa similar search strategywould
yieldsofewstudies.No(weighted)meanswerecalculated.




depression’) was not accounted for in some of the studies and may have lead to
overdiagnosis. The exclusion of publications stemming from the same database is a
strength of this review. However, although the authors have tried to identify such
publications,wemaynothavebeenawareof themall.Another strengthof this sys
tematicreviewincomparisontootherreviewsisthatarticlesareselectedonbasisof
quality criteria, which at the same time could be seen as a limitation. The quality
criteriausedforinclusionarechosenbytheauthorsandthussubjective.However,the
criteria are consistent with general recommendations for evidencebased research.
Because of this, several studies, reporting the prevalence of depression in PD, were
excludedbecausetheydidnotdescribethediagnosticcriteriausedforPDordepres
sion, or did not adequately describe the selection procedures used. In addition, the
validity of rating scales used to diagnose depression and the appropriateness of the
cutoff scoremay also be subject to criticism. Finally, any systematic review is influ
encedbythelimitationsoftheincludedstudiesthemselves.Onesuchlimitationisthe







ofmajordepressivedisorder inPD is17%, theprevalenceofdysthymia is13%,while
minor depression occurs more frequently, in 22% of PD patients. Although these
prevalences are lower than previously reported, this systematic review nevertheless
confirmsthatdepressionisacommoncomplicationinpatientswithPD.
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Abstract 




consisting  of  the  Structured  Clinical  Interview  for DSM  IV major  depressive  disorder 
(SCID‐D),  as  well  as  the  HAMD  and  MADRS.  Sensitivity,  specificity,  positive,  and       
negative predictive values for a range of cut‐off scores were calculated for both rating 
scales  and  for  modified  versions  of  these  scales  in  which  all  somatic  items  were      
eliminated. In addition, receiver operating characteristic curves were obtained for both 
the modified and unmodified scales. 




for  diagnostic  purposes;  for  screening  purposes,  the  abbreviated  version  without    
somatic  items  can  be  used.  Additional  advantages  of  using  full  rating  scales,  with    
somatic  items  included,  are  that  these  provide more  information  on  the  severity  of 
depression and allow for easier comparison across studies. 
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CHAPTER  3 
3.1 Introduction
Parkinson’s disease (PD) is a neuropsychiatric disorder, characterized by bothmotor
and nonmotor symptoms. Depression is probably the most common nonmotor
symptom1.DSMIVdefinedmajordepressivedisorderoccursin17%ofPDpatientsand







of PD may mimic symptoms of depression even in euthymic patients. As the most
commonlyuseddepressionratingscales,suchastheHamiltonDepressionRatingScale
(HAMD) and MontgomeryÅsberg Depression Rating Scale (MADRS) 4, 5, invariably
incorporate a number of these physical items, many authors have expressed their




all symptoms are considered to be related to depression, regardless of their overlap
with PD 10, 11. Rather than interpreting symptoms, a correction for higher depression
scoresduetooverlappingsymptomsofdepressionandPDcanbemadebyadjusting




lacksomatic items,providedthat thesesomatic items inPDdonotcontribute to the
diagnosticperformanceintheevaluationofdepressioninPD.However,somesomatic
symptoms accompanying depression, especially reduced appetite and early morning
wakening, have been shown to bemore specific for depression than for PD 13. The
present study aimed at evaluating the influence of somatic items on the clinimetric
performanceoftheHAMDandMADRSinpatientswithPD.
3.2 Patientsandmethods
As part of an ongoing research project on psychopathology in PD, 254 consecutive
patients with primary PD, as defined by the clinical criteria of the United Kingdom
Parkinson’sDiseaseSocietyBrainBank(UKPDSBB),werereferredfromtheneurologi
cal outpatient department for a protocolized mental status examination 14. This
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examinationconsistedoftheStructuredClinicalInterviewforDSMIVDepression(SCID
D), to confirmor reject thediagnosisofmajordepressivedisorder asdefinedby the
criteriaoftheDSMIV15.Aninclusiveapproachtothediagnosticcriteriawasfollowed
in accordance with recommendations of international task forces 10, 11. The DSM IV
diagnosisofmajordepressivedisorderwasconsideredthegoldstandardinthisstudy.
Patients fulfilling theDSM IV criteria fordementia, assessmentbasedon anunstruc




system; thecognitive statusof thepatientswasassessedwith theMiniMentalState
Examination(MMSE)16,17.Allinterviewsandscaleswereadministeredbytrainedstaff.
Receiveroperatingcharacteristic (ROC)curveswereobtainedforboththeHAMDand
theMADRS 18. This curve plots the ‘sensitivity’ versus ‘1minus specificity’ for every
possiblecutoffpoint.Forbothscales,twocurveswereobtained:onecurveforthefull
ratingscale,includingallsomaticitems,andoneforamodifiedversionofthescalein
which the somatic items had been eliminated. In themodified HAMD, the following
items were eliminated (item number between parentheses): disturbances of sleep
(46), psychomotor slowing (8), physical anxiety (11), reduced appetite (12), fatigue
(13), reduced sexual interest (14), andweight loss (16). In themodifiedMADRS, the
following items were eliminated: sleep disturbances (4), reduced appetite (5), and
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3.3 Results
Of the254 referred patients, 30 (11.8%)were excludedbecause of dementia. In the
analysisofHAMD items,224patientsparticipated:135menand89women,withan
average age of 65.6 years (SD 10.4). Their average MMSE score was 27.7 (SD 2.3).
AccordingtotheH&Yscale,17patientswereclassifiedasStageI,129asStageII,55as













significant differences between the depressed and nondepressed patients for age,
H&Y,andMMSEscore(t(152)=0.60,p=0.549;t(152)=0.18,p=0.857;t(152)=0.61,
p=0.542,respectively).
Sensitivity, specificity, positive, and negative predictive values for different cutoff
scoresareshowninTables1and2forthefullversionandthemodifiedversionofthe
HAMD, and for theMADRS in Tables 3 and 4. For theHAMD17, theoptimal cutoff




sensitivity 0.98, specificity 0.71). For theMADRS, the optimal cutoff score is 13/14
(Youdenindex1.59:sensitivity0.79,specificity0.80).ForthemodifiedMADRS,without
somatic items, the optimal cutoff score is 5/6 (Youden index 1.68: sensitivity 0.93,
specificity0.75).
 39
MOOD & MOT IVAT ION  I N  P ARK INSON ’ S  D I S EAS E 
Table1. Sensitivity,specificity,positive,andnegativepredictivevaluesatdifferentcutoffscoresforthe
  17itemHAMD
Cutoff 8/9 9/10* 10/11 11/12 12/13 13/14 14/15 15/16 16/17
Sensitivity 1 0.98 0.92 0.84 0.79 0.74 0.63 0.61 0.50
Specificity 0.65 0.75 0.80 0.85 0.89 0.94 0.96 0.96 0.98
PPV 0.37 0.45 0.48 0.53 0.60 0.72 0.75 0.77 0.82






Cutoff 3/4 4/5* 5/6 6/7 7/8 8/9 9/10 10/11 11/12
Sensitivity 0.97 0.98 0.87 0.76 0.58 0.50 0.40 0.32 0.32
Specificity 0.64 0.71 0.81 0.87 0.94 0.96 0.99 1 1
PPV 0.36 0.41 0.48 0.55 0.65 0.73 0.88 0.93 1





Cutoff 9/10 10/11 11/12 12/13 13/14* 14/15 15/16 16/17 17/18 18/19
Sensitivity 0.93 0.86 0.79 0.79 0.79 0.72 0.69 0.66 0.55 0.52
Specificity 0.61 0.63 0.72 0.75 0.80 0.86 0.89 0.90 0.91 0.93
PPV 0.35 0.35 0.40 0.43 0.48 0.54 0.59 0.59 0.59 0.62





Cutoff 4/5 5/6* 6/7 7/8 8/9 9/10 10/11 11/12 12/13 13/14
Sensitivity 0.97 0.93 0.83 0.72 0.72 0.69 0.66 0.59 0.55 0.38
Specificity 0.69 0.75 0.79 0.82 0.86 0.90 0.91 0.94 0.98 0.98
PPV 0.42 0.47 0.48 0.49 0.54 0.62 0.63 0.71 0.84 0.79
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ThesensitivityoftheHAMDattheoptimalcutoffscore(9/10)is0.98.Thesensitivityof
themodifiedHAMDat theoptimal cutoff score (4/5)wasalso0.98.Comparisonsof
the specificity of the HAMD17 (0.75) and themodified HAMD (0.71) at the optimal
cutoff scores showed that the difference was statistically significant (Fisher's Exact
Test, p > 0.0005). Comparisons of the sensitivity and specificity of the MADRS
(sensitivity0.79,specificity0.80)andthemodifiedMADRS(sensitivity0.93,specificity
0.75)at theoptimal cutoff scores showed that thedifferenceswerealso statistically
significant(Fisher'sExactTest,p=0.037;Fisher'sExactTest,p>0.0005).
At theoptimal cutoff score, thepercentagecorrectly classifiedwith theHAMD17 is
79%and75.5%withthemodifiedHAMD.WiththeMADRSandmodifiedMADRS,the





theMADRSwithandwithout somatic itemsare shown inFigure2.TheAUCs for the
MADRSwithandwithoutsomaticitemsare0.880and0.912,respectively.Comparisons
of the two AUCs showed that the difference is statistically significant (z = 2.14,
p=0.033).
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did not result in a significant change of the AUC in patients with PD. Elimination of
somatic itemsofdepressionfromtheMADRSresulted inasignificant increaseof the
AUC.TheROCcurvesgiveusanindicationoftheoverallclinimetricperformanceofthe
scales. However, we also looked more specifically at the influence of eliminating
somatic items on the screening and diagnostic value of the scales. The sensitivity
(screening value)of theHAMDof theoptimal cutoff score remained the sameafter
elimination of somatic items (0.98). The specificity (diagnostic value) of the optimal
cutoff score showed a significant decrement after elimination of the somatic items
(respectively,0.75withsomaticitemsand0.71withoutsomaticitems).
For theMADRS, there is a significant incrementof the sensitivityaftereliminationof
the somatic items (respectively, 0.79 with somatic items and 0.93 without somatic
items).Thespecificityoftheoptimalcutoffscoresignificantlydecreasedafterelimina
tion of the somatic items (respectively, 0.80 with somatic items and 0.75 without
somaticitems).
Since our gold standard for depression, the DSM IV criteria of major depressive
disorder, contains a number of somatic criteria that are also part of the HAMD and
MADRS,eliminationofthesesomaticitemsintheratingscaleswasexpectedtoreduce
the concurrent validity of these scales with the DSM IV criteria ofmajor depressive
disorder.Thepercentagescorrectlyclassifiedindeedshowedareductionafterelimina
tionofthesomaticitems.











in this study. Thismeans that patients were assessed by different staffmembers. A
thirdlimitationisthattheremaybeconfoundinginfluencesofcomorbidityotherthan
PDorbymedication,whichwedidnottakeintoaccount. 
In general, depression rating scales should not be used for diagnostic purposes: a
diagnosisrequirestheuseofdiagnosticcriteria11.Eliminatingsomatic itemsfromthe
HAMD and MADRS results in a reduced specificity of both scales and an increased
 43




for screening. Additional advantages of using full rating scales, with somatic items
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Abstract
Background: In Parkinson’s disease (PD) it has been suggested that various motor
subtypes are also characterized by a different prevalence and severity of specific




logical symptoms was performed with a randomized sample of 173 patients each,
stemming from two research databases: one from StavangerUniversityHospital and
onefromMaastrichtUniversityHospital.Thesedatabasescontaineddataofstandard
ized assessments of patients with the Unified Parkinson’s Disease Rating Scale, the
MontgomeryÅsbergDepressionRatingScale,andtheMiniMentalStateExamination.
Results: PD patients can be accurately and reliably classified into four different
subtypes: rapid disease progression subtype, youngonset subtype, nontremor










Parkinson’s  disease  (PD)  is  increasingly  considered  a  neuropsychiatric  disorder,        
characterized  by  both  motor  and  non‐motor  symptoms.  Motor  symptoms  include  




sive  disorder  occurs  in  17%  of  patients  and  minor  depression  in  22%  2.  Apathy  is      
reported  in  16.5%  to  40%  of  PD  patients  3,  4.  Dementia  occurs  in  24  to  31%  and        
hallucinations in up to 40% 5, 6. 
The  clinical presentation of  the motor  symptoms  in PD may  vary,  and different  sub‐
types have been described,  such  as  a  ‘hypokinetic‐rigid’,  a  ‘tremor‐dominant’,  and  a 
‘postural instability‐gait disorder’ form 7, 8. Although clinically recognizable, these motor 
subtypes  have  not  been  the  subject  of  extensive  research.  Moreover,  it  has  been    
suggested  that  the  various  motor  presentations  of  PD  are  also  characterized  by  a    
different risk and severity of specific non‐motor symptoms such as depression, apathy, 
and cognitive problems. A higher prevalence and severity of depressive symptoms has 
been described  in  the  ‘hypokinetic‐rigid’ group compared  to  the  ‘classic’  (tremor plus 






A  total of 350 patients with PD as defined by  the Queens Square Brain Bank  criteria 
participated  in  the analysis  12. To  this end,  two databases, containing epidemiological 
data  of  standardized  assessments  using  the  same  instruments,  were  combined  to   
increase  sample  size. One database was  from a population based  study of Stavanger 
University Hospital and one  from an outpatient based  study of Maastricht University 



































Comparison of populations between the two institutions was done with ttests for
continuousvariables.Akmeansclusteranalysiswasperformedwiththestandardized
scores of the following variables (see Table 1): tremor, hypokinesia/rigidity, PIGD,
Ldopacomplications,diseaseprogression,ageatdiseaseonset,cognition,depression,




with post hoc multiple comparisons. All reported test results are twotailed and a
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The total sample consisted of 350 PD patients; 224 from Stavanger and 122 from
Maastricht. Table 2 shows the differences inmean age, disease duration, H&Y, ADL,
cognition(MMSEscore),anddepression(MADRSscore)betweenpatientsfromthetwo





results in a total sample size of 346. Patients from the combined database were
randomly assigned to one of two samples, each containing 173 PD patients.
Independent sample ttests showed that therewerenodifferencesbetween the two
samplesforage,diseaseduration,H&Y,ADL,cognition(MMSEscore),anddepression
(MADRS score) (t(344)=1.12,p=0.266; t(344)= 1.56,p=0.121; t(344)=0.53,p=











Age 73.2(8.4) 65.3(10.0) 7.86 <0.0005
Diseaseduration 9.0(5.7) 6.7(5.0) 3.70 <0.0005
H&Y 2.8(1.0) 2.4(0.8) 3.45 <0.0005
ADL(UPDRSpart2) 14.1(8.5) 14.3(5.9) 0.28 0.779
Cognition(MMSEtotalscore) 25.0(5.8) 27.7(2.4) 4.99 <0.0005
Depression(MADRStotalscore) 8.0(6.3) 11.8(7.2) 5.04 <0.0005
H&Y:Hoehn&YahrRatingscale;ADL:Activityofdailylife;PIGD:Posturalinstabilitygaitdifficulty
Explorativeclusteranalysis
The first sample (n=173) was used for an explorative cluster analysis. Patients were
classified in four clusters, based on changes in cluster distances between successive
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stepsandtheclinicalfacevalidityoftheclusters.Table3showsthefinalclustercenters
forthefourclusters.Thefirstpatientprofile(cluster1)comprised6.4%ofthesample.




thisclusterhavea relative lowageatdiseaseonset,comparedto thepatients in the
other three clusters. Thepatients also scoredhighon levodopa complications. These
patientsare,therefore,describedas‘youngonset’.Thethirdpatientclustercomprised
16.8% of the sample. These patients scored high on the hypokineticrigid and PIGD




scores on psychopathological measures. This cluster is, therefore, typed as ‘tremor
dominant'.
A chisquare test showed that there is no association between the two institutions
(StavangerandMaastricht)andthefourclusters(2(3)=0.58,p=0.902).Thismeans
that cluster membership is independent of institution. For clarification, the






 1 2 3 4
Zscore:Tremor ,17 ,48 ,34 ,19
Zscore:Hypokinesia/rigidity ,48 ,06 ,91 ,53
Zscore:PIGD ,31 ,12 1,06 ,43
Zscore:Ldopacomplications ,22 1,04 ,01 ,53
Zscore:Diseaseprogression 2,37 ,51 ,03 ,14
Zscore:Ageatdiseaseonset ,71 ,97 ,15 ,21
Zscore:Cognition ,21 ,49 1,52 ,32
Zscore:Depression ,07 ,31 ,99 ,61
Zscore:Apathy ,05 ,05 ,95 ,52
Zscore:Hallucinations ,22 ,17 1,21 ,27
PIGD:Posturalinstabilitygaitdifficulty
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Confirmationoftheexplorativeclusteranalysis
To establish classification accuracy the four clusters determined by the explorative
kmeanclusteranalysiswerecomparedwiththeirclusterassignmentdeterminedbya






the fourclusters.Patientswereassignedtoaspecificcluster if the followingdecision
rulesweremet:theirposteriorprobabilityofbelongingtotheclusterwasatleast0.66
and a chisquare test of their generalized squareddistance from the cluster centroid














and 3 have significant higher disease duration than patients from cluster 1 and 4
(t=8.17,p<0.0005;t=3.68,p=0.001;t=9.10,p<0.0005;t=4.60,p=0.001).
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Comparable results were found by using sample 2 instead of sample 1. The analysis on 
























Age  72.5 (9.0)  63.3 (10.5)  75.7 (7.7)  71.4 (7.8) 
Disease duration  2.6 (1.3)  10.8 (5.1)  11.7 (7.1)  7.1 (5.1) 
H&Y  3.0 (1.2)  2.6 (0.6)  3.7 (0.8)  2.2 (0.7) 
ADL  15.7 (5.3)  12.6 (5.7)  21.8 (6.7)  11.5 (6.0) 
Tremor  0.9 (0.6)  0.6 (0.6)  0.7 (0.8)  1.1 (0.8) 
Hypokinesia/rigidity  1.9 (0.5)  1.4 (0.6)  2.2 (0.8)  1.1 (0.6) 
PIGD  1.3 (0.5)  0.9 (0.6)  1.9 (0.6)  0.7 (0.6) 
L‐dopa complications  1.8 (3.5)  5.8 (4.0)  2.5 (2.5)  0.7 (0.8) 
Disease progression  21.3 (17.5)  3.9 (2.4)  5.9 (2.6)  5.9 (4.1) 
Age at disease onset  69.9 (8.2)  52.6 (9.4)  64.0 (8.4)  64.3 (7.6) 
Cognition (MMSE total score)  24.0 (4.7)  28.2 (1.8)  17.4 (7.7)  27.7 (2.3) 
Depression (MADRS total score)  8.7 (5.2)  11.5 (6.7)  15.7 (6.4)  5.3 (4.2) 
Apathy (UPDRS item 4)  1.1 (0.7)  1.1 (0.9)  2.0 (0.8)  0.6 (0.7) 






analyses  to  establish  different  subgroups  of  PD  patients.  Graham  and  Sagar  (1999) 
performed a cluster analysis with 176 PD patients and revealed three distinct subtypes; 
motor only  subtype, motor and  cognitive  subtype, and  rapid progression  subtype  18. 
Lewis et al.  (2005) used a  sample of 120 early PD patients, which  revealed  four  sub‐
groups;  young  disease  onset  group,  tremor‐dominant  group,  non‐tremor‐dominant 
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significant levels of cognitive impairment and mild depression and a rapid disease
progression group 17. The groups identified in our study are in agreement with the
studyofLewis(2005).
Further validation of thesemotor groups was done with demographical and clinical
variablesthatwerenotusedintheoriginalclusteranalysis.Thenontremordominant
groupischaracterizedbyahigherageandmoreseveremotorsymptoms.Thesefactors
have previously been associated with cognitive decline in PD 11. Moreover,
bradykinesia22andposturalinstabilitygaitdifficultyarealsoassociatedwithcognitive
decline10,11.




relation of apathetic symptoms to one of the motor presentations of PD. Several
studies have associated hallucinations with more severe motor symptoms, but no






Our study also has several limitations. First of all, population characteristics of the
StavangerandMaastrichtsampleturnedouttobedifferent.Thisisprobablyduetothe






institution.A second limitation is that thepsychopathological symptoms ‘apathy’and
‘hallucinations’were assessedwith individual items of theUPDRS. These itemswere
notmeantto,norvalidatedtobeusedoutsidethecontextoftherespectivefullscale.
A third limitation is sample size. Our sample size was such that a maximum of 10




may have implications for further research into the underlying pathophysiology of
psychopathology in PD. In the hypokineticrigid more severe cell loss in the
ventrolateral part of substantia nigra (SN) and dopaminergic loss in the posterior
putamen has been described, which causes inhibition of the glutamatergic
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thalamocorticalpathwayandreducedcorticalactivation.Thetremordominantformis
characterized by more severe cell loss in the medial SN, which project to the





Summarizing, our study shows that PD patients can be classified into four different
subtypeswithhighaccuracyandvalidity.Thesecomprisea rapiddiseaseprogression
group,ayoungonsetgroup,anontremordominantgroupwithpsychopathologyanda
tremordominant group. Psychopathology, including depressed mood, apathy,
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Abstract
Background: Apathy is a common neuropsychiatric syndrome in Parkinson’s disease
(PD)thataffectsqualityof life.Research intoapathyhasbeenhamperedbya lackof




Design and methods: In a crosssectional study, outpatients with PD visiting a





criteria. Acceptability and internal consistency of the criteria was good, as was the
concurrentvaliditywiththeLARSandapathysectionoftheNPI.Discriminantvalidityof
the criteria with depression was moderate to good. All domains of criterion B
(behaviour, cognition, emotion) contributed to the diagnosis of apathy, of which
reducedgoaldirectedbehaviourwasthemostfrequentlyobservedsymptom.








been  reported,  depending  on  the  population  characteristics  and  assessment            





Research  into  apathy has been hampered by  a  lack of  generally  accepted diagnostic 
criteria  9.  In  2008,  a  consensus  meeting  was  held  by  the  European  Psychiatric           
Association  (EPA),  the  European  Alzheimer’s  Disease  Consortium  (EADC),  the           
Association  Française  de  Psychiatrie  Biologique  (AFPB),  and  invited  experts  from 
Europe,  Australia,  and  North  America,  to  propose  consensus  diagnostic  criteria  for 
apathy  as  a  syndrome  10  (Table  1).  These  proposed  diagnostic  criteria  have  sub‐       
sequently been   validated  in 306 patients  suffering  from a  range of neuropsychiatric 
diseases  including  Alzheimer’s  disease  (AD),  mixed  dementia,  Mild  Cognitive            









One  hundred  and  twenty‐two  patients  from  Lille  University  Medical  Centre,  Lille, 
France, and Maastricht University Medical Centre, Maastricht, the Netherlands, under‐
went  a  single  assessment.  All  patients  suffered  from  idiopathic  PD  according  to  the 
Queens  Square  Brain  Bank  criteria  13.  Patients were  excluded  if  they  suffered  from  
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disordersasdefinedbythecriteriaofthefourtheditionoftheDiagnosticandStatistical
Manual(DSMIV)oftheAmericanPsychiatricAssociation(APA)wasassessedwiththe
Mini International Neuropsychiatric Inventory (MINI, a structured interview for DSM
disorders)sectionsA(depressivedisorder),andB(dysthymia)15.Severityofdepressive
symptoms was assessed with the 17item Hamilton Depression Rating Scale
(HAMD) 18, 19. Trained psychologists assessed the diagnostic criteria for apathy by
means of an unstructured clinical interview. All criteriawere individually questioned
and additional information of the caregiver, if available, was used in the scoring
procedure. Following criterionD of the diagnostic criteria, domain B1, reduced goal
directed behaviour, was only scored if it was thought not to be directly related to







thediagnostic criteria. TheNPI requires information froma caregiver. If thiswasnot
available, information was collected from the patient if this information, in the
researcher’sopinion,wasreliable.
Statisticalanalysis
All statistical analyses were conducted using the Statistical Package for the Social
Sciences,version16.0(SPSS,Chicago).To identifydifferences inscores,KruskalWallis
tests were used since none of the included variables were normally distributed.





Concurrentvalidityof thediagnostic criteriawith theLARSand theapathysectionof
theNPIwasestimatedbycalculatingPhi correlationcoefficients.Apathywasdefined
hereasscoreontheLARSof1621orasascoreof4ontheapathysectionofthe
NPI. A correlation < 0.3 was considered weak, a correlation between 0.3 and 0.5
moderate, between 0.5 and 0.7 fair, and > 0.7 good. Knowngroups validity was
assessed by comparing average scores obtained by apathetic and nonapathetic
patients on the LARS and the apathy section of the NPI, using a KruskalWallis test.
Discriminant validity between the diagnostic criteria of apathy and those of major
depressivedisorder,aswellaswiththeHAMDscoreandthescoreonthedepression
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sectionoftheNPI,wasalsoestimatedbycalculatingPhicorrelationcoefficients.Inthis
case,lowercorrelationcoefficientswerethoughttoreflectbetterdiscriminantvalidity.
The frequency of each of the three domains of criterion B in apathetic and non
apathetic patients was reported and tested for differences by chisquare tests. The
scores on subscales of the LARS in apathetic and nonapathetic patients were also
compared and tested for differences with a Kruskal Wallis test. The relationship











score of 24.6 for patients from Lille versus 22.2 for patients from Maastricht;
p = 0.048). However, these differences were small and not considered clinically
relevant.
Patients meeting the diagnostic criteria for apathy scored significantly lower on the
MMSE,andhigherontheHAMD,theLARSandtheapathysectionoftheNPIthannon
apathetic patients. For the IADL score, a trend towards lower (worse) scores for
apatheticpatientswasobserved(p=0.059).
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Age 64.6(8.5) 64.2(8.7) 64.6(8.5) 0.844 63.4(8.1) 65.7(8.7) 0.138
Female(%) 41 42,9 40.6 0.939 57 38 0.558
Disease
duration
8.5(5.6) 7.5(5.7) 8.7(5.6) 0.220 9.6(6.3) 7.5(4.6) 0.099
H&Ystage
(median)
2(3) 2(3) 2(3) 0.298 2(3) 2(3) <0.001
UPDRSIII 19.4(8.0) 21.8(7.0) 18.9(8.2) 0.050 20.7(9.3) 18.1(6.2) 0.063
MMSE 28.2(1.8) 27.2(2.1) 28.5(1.6) 0.010 28.0(1.9) 28.5(1.6) 0.150
IADL 18.2(6.2) 21.4(8.7) 17.6(5.3) 0.059 16.9(5.4) 19.7(6.6) 0.001
HAMD 6.3(5.8) 13.0(6.9) 5.0(4.4) <0.001 6.2(6.2) 6.5(5.3) 0.346
NPIapathy 1.6(2.8) 6.4(3.0) 0.6(1.2) <0.001 2.0(3.3) 1.2(2.0) 0.392




















 Apathetic Nonapathetic Total
Nodepression 10(8.2%) 91(74.6%)** 101(82.8%)
Majordepressivedisorder 7(5.7%) 6(5.0%)** 13(10.7%)
Dythymia 4(3.3%) 4(3.3%)* 8(6.6%)
Total 21(17.2%) 101(82.8%) 122(100%)
*p0.01,**p<0.001
Validity












tion, and thus good discriminant validity. For the HAMD, the correlation was 0.54
(p=0.01),indicatingamoderatecorrelation,andthusamoderatediscriminantvalidity.
Knowngroupsvaliditywasassessedbycomparingthescoresoftheapatheticandnon

















Apathetic 18(86%) 3(14%) 17(81%) 4(19%) 21
Nonapathetic 6(6%) 95(94%) 6(6%) 95(94%) 101
Total 24(20%) 98(80%) 23(19%) 99(81%) 122
Subdimensionsofapathy
Table5illustratesthatallthreedomainsofapathydescribedincriterionBcontributeto
the diagnosis of apathy. In apathetic patients, reduced goaldirected behaviour (B1)
was themost frequently observed domain (95%), followed by reduced goaldirected
cognition(B2,86%)andreducedspontaneousemotion(B3,52%).Ofthe21apathetic
patients, 38.1% scores positive on all three domains of criterion B, 47.6% scored on
domainsB1andB2only,9.5%ondomainsB1andB3only,and4.8%ondomainsB2and
B3only.
When comparing scores on the LARS domains and subscales between apathetic and




(behaviour) correlated fairwith the subscale ‘intellectual curiosity’, but onlyweak to







 B1 B2 B3 Total
Apathetic 95.2% 85.7% 52.4% 21
Nonapathetic 23.8% 12.9% 9.9% 101

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Everydayproductivity 2.10(1.87) 3.21(1.12) 0.003
Interest 0.19(2.23) 1.73(1.40) <0.001
Takinginitiative 1.05(2.04) 3.25(1.16) <0.001
Noveltyseeking 0.19(2.04) 2.78(1.71) <0.001
Motivation 0.90(2.45) 3.21(1.42) <0.001
Emotionalresponses 1.86(1.82) 3.23(1.17) <0.001
Concern 2.52(1.72) 2.78(1.38) 0.632
Sociallife 0.62(2.18) 2.65(1.43) <0.001
Selfawareness 2.52(2.11) 2.99(1.45) 0.574
   
Intellectualcuriosity 0.40(1.03) 2.61(0.85) <0.001
Emotion 2.12(1.08) 3.01(0.99) 0.001
Actioninitiation 1.55(1.43) 3.25(0.86) <0.001











Intellectualcuriosity 0.557** 0.622** 0.346**
Emotion 0.236** 0.204* 0.327**
Actioninitiation 0.323** 0.466** 0.199*
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5.4 Discussion
Thisisthefirststudythatvalidatestherecentlyproposeddiagnosticcriteriaforapathy
in a population of patients with PD, with the aim of assessing their usefulness for
clinicalpracticeandresearch.Onlyoneearlierstudytestedthecriteriainpatientswith
a range of neuropsychiatric diseases 11. New instruments or criteria are generally
validated against an existing gold standard. For apathy, no gold standard is available
yet,whichsetslimitationstotheassessmentofclinimetricpropertiesoftheproposed
criteria.Whilereliabilitycanbeassessed,assessingvalidityposesaproblem,sincethis
requires a gold standard. For assessment of concurrent validity and knowngroups
validity,theLARSandapathysectionoftheNPIwereusedas‘proxygoldstandard’.The
NPI is a frequently used instrument in neurodegenerative disorders (including PD),
while the LARSwasdesigned specifically forPDpatients 22. Forboth scales,weused
proposed cutoff scores for apathy in accordance with those used in previous
studies2022.Ourstudyshowsthatthediagnosticcriteriaforapathyhavegoodinternal
consistencyandacceptability.Strongcorrelationswere foundbetweenthediagnostic
criteria for apathy, and both the LARS and apathy section of the NPI, which implies
goodconcurrentvalidity.Knowngroupsvaliditywasalsogood.Discriminantvalidityof
theapathycriteria todistinguishapathyanddepressivedisorderasdiagnosedonthe
basis of theMINI was good.When discriminant validity of the criteria was assessed
using the HAMD or depression section of the NPI as indicator of depression, this
discriminantvaliditywasgoodagainsttheNPIdepressionsectionandmoderatewhen
theHAMDisused.ApossibleexplanationforthisdifferenceisthefactthattheHAMD





17 to 70%, mostly on the basis of cutoff scores on a rating scale or assessment
instrument13.Thus,thefrequencyfoundinthisstudyisinthelowerpartofthatrange.
Onepotential explanation for thismaybe the fact thatwedidnot includedpatients
withaclinicaldiagnosisofPDD,whereasthefrequencyofapathyishigherinpatients
withcognitivedeclineanddementia.ThiswassupportedinarecentstudyofDujardin
and colleagues inwhich24.2%of the nondemented PDpatients had apathy against
56.4% among the demented patients 2. In an earlier validation study of the same
criteria,afrequencyofapathyof27%in44PDpatientswasreported11.However,this
studyincludedPDpatientswithandwithoutdementia.Inlinewithourstudy,thislatter
study also suggests that the diagnostic criteria for apathy have a relatively higher
threshold,whencomparedtocutoffscoresonapathyratingscales.
AlldomainsoftheBcriterioncontributedtoadiagnosisofapathy,withgoaldirected
behaviourbeing themost frequent reporteddomain.Domain3,emotion,appears to
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score on the apathy section of the NPI was significantly higher in patients meeting
criterionB3(8.2versus4.5;p=0.005),whereasthemeanscoreontheLARSwasnot
differentforthosethatdidordidnotmeetcriterionB3(10.9versus12.9;p=0.75).
Our studyhad several limitations. Firstofall, the includedpatientswere recruited in
twodifferentcenters.Inbothsettings,differentratersperformedtheassessment.For
practical reasons, interrater reliabilitywas not assessed aswell were the raters not
blindtootherassessmentscales.Anotherlimitationisthatpatientswithadiagnosisof
PDD were excluded from the study while it is known that dementia predisposes to
apathy1.Exclusionofthesepatientscouldgiveanunderestimationofthefrequencyof
apathyinPDandmayexplaintherelativelylowfrequencyofapathyfoundinthisstudy.
However, it underlines that in a clinical population of PD patients with andwithout
cognitivedecline,apathyisaquitefrequentneuropsychiatricsyndrome.
Conclusion
This study shows good acceptability, internal consistency, concurrent, and known
groupsvalidityoftheproposeddiagnosticcriteriaforapathy.Inaddition,discriminant
validitywithdepression ismoderatetogood.AlldomainsofcriterionBcontributeto
the syndromal diagnosis, of which diminished goaldirected behaviour was most
frequent.Lackofemotion ispossibly related toamoresevere levelofapathy.These
properties make the proposed criteria valid, and useful for clinical practice and
research. The criteria provide a gold standard for studies into the epidemiology,
symptomatology,pathophysiology,andtreatmentofapathyinpatientswithPD.Future
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Abstract
Background:Apathyisgenerallydefinedasadisorderofmotivationandisconsidered




examination, and a 3 teslamagnetic resonance imaging scanwas acquired. A voxel
based multiple regression analysis was used to calculate correlation between grey
matterdensityandseveritymeasuresofapathy.
Results: Apathy correlateswithdecreasedcognitive functioningandmoredepressive
symptoms but not with more severe motor symptoms. High apathy scores were
correlatedwithlowgreymatterdensityvaluesinanumberofcorticalbrainareas:the
bilateral precentral gyrus (BA 4, 6), the bilateral inferior parietal gyrus (BA 40), the








CHAPTER  6 
6.1 Introduction
Apathy is defined as a disorder of motivation and is considered one of the most
commonneuropsychiatricdisturbances inParkinson’sdisease (PD),occurring inupto
70% of patients 1. Apathy is characterized by diminished motivation and effort to
perform everyday activities, lack of intellectual interest and initiative regarding
personalandsocial issues,andindifferenceorflatteningofaffect24.Althoughapathy
overlapswithdepression,severalstudieshaveshownthatapathyanddepressionare
different constructs 5, 6. Apathy has been associatedwith decreased quality of life 7,
decreasedperformanceonactivitiesofdaily living(ADL)7,andmoreseverecognitive
dysfunction,morespecificallyexecutivedysfunction810.ArecentstudyofPedersenet
al. (2009) reported that dementia and a more rapid decline in speech and axial
impairment,featurespredominantlyassociatedwithdysfunctionofnondopaminergic
subcorticalstructures,wereindependentriskfactorsforapathyinPD11.




with severityofapathy 5.APETstudyofRemyetal. (2005) showed thatapathywas
inversely correlated with 11CRTI32 binding (dopamine and noradrenaline) in the
ventralstriatumbilaterally13.AnotherPETstudybyLeJeuneetal.(2009)investigated
apathy in PDpatients afterdeepbrain stimulation (DBS) of the subthalamic nucleus.
Theyshowedthatpostoperativeapathyscoreswerecorrelatedwithdecreasedglucose
metabolisminthebilateralposteriorcingulategyrusandleftmiddlefrontalgyrus14.
The objective of our study is to investigate the structural correlates of apathy,
correlatingthelevelofapathywithanatomicalchangesingreymatterdensityderived




Sixty consecutive outpatients with idiopathic PD, visiting the Neurology Clinic or the
MemoryClinicofMaastrichtUniversityMedicalCentre,wereincluded.Thediagnosisof
idiopathic PD was established by use of the Queens Square Brain Bank criteria 15.
Exclusion criteriawereneurological or psychiatricdiseasesother thanPD, theuseof









All patients underwent a neuropsychiatric examination, a neuropsychological test
battery, and a 3 teslaMRI scan on the same day. The neuropsychiatric examination
includedpart3oftheUnifiedParkinson’sDiseaseRatingScale(UPDRS)17tomeasure
theseverityofmotorsymptoms, theHoehnandYahrstagingscale (H&Y)18 toassess
disease stage, the 17item Hamilton Depression Rating Scale (HAMD) 19 to measure
depressive symptoms and the Neuropsychiatric Inventory (NPI) 20, 21 to assess the
presence and severity of 12 neuropsychiatric disturbances (delusions, hallucinations,
agitation,depressedmood,anxiety,apathy,irritability,euphoria,disinhibition,aberrant
motorbehaviour,nighttimebehaviourdisturbances,andeatingabnormalities).
Inaddition theApathyEvaluationScale (AESI) 22, 23 and the LilleApathyRatingScale
(LARS) 24wereused toassessapathy.TheLARSprovidesanoverallapathyscoreand
four composite subscores thatpresumably reflect fourdistinctdimensionsofapathy:
intellectual curiosity, action initiation, emotion, and self awareness 25. Apathy was
measuredwiththreedifferentscalesinordertocomparetheresultsofthesescales.
Theneuropsychological testbattery included thecognitiveand selfcontainedpartof
the Cambridge Examination forMental Disorders of the Elderly part B (CAMCOG) 26
whichincorporatestheMMSE16.Subdomains intheCAMCOGare:attention,orienta
tion, language comprehension, expression, memory, praxis, abstract reasoning, and
perception.
MRImagingDataAcquisition
MRI scanswere acquiredwith a 3.0 teslaGyroscanNTMRI scanner (PhilipsMedical
Systems, Best, the Netherlands). A coiled gradient was used, which provided high
anatomicalresolutionandgoodgrey/whitemattercontrastforsubsequentsegmenta





CHAPTER  6 
VoxelBasedMorphometry
Image preprocessing was performed using Statistical ParametricMapping 8 (SPM 8)
(WellcomeTrustCentreforNeuroimaging,London).Thefirststepwasa12parameter






more detail in Karas et al. (2004) 28 andWoods et al. (2003) 29. The registered grey
mattervolumesweresmoothedusingaGaussiankernel filtersetat10mm(fullwith




analysis to calculate linear correlations between greymatter density and severity of
apathyassessedwithdifferentscales.Morespecifically,theLARStotalscoreandfour
subscores for different domains of apathy (intellectual curiosity, action initiation,





for statistical significancewas set at p < 0.05 corrected formultiple comparisons by
false discovery rate correction; subsequently suprathreshold clusters were further
filteredtop<0.1,correctedformultiplecomparisons.
Thex,y,andzcoordinatesofareaswithasignificantcorrelationbetweengreymatter




for Social Sciences version 16.0 (SPSS, Chicago). Descriptive statistics were used to
describethedemographicalandclinicalcharacteristicsofthePDpatients.FisherExact
tests were used to compare proportions. Normality and linearity check was
performedbeforePearson’scorrelationcoefficientswerecalculatedtodeterminethe
relationships between the several apathy assessments and the demographical and
clinicalcorrelates.Correlationcoefficients<0.3 (percentexplainedvarianceR2of less
than 9%) were considered weak; between 0.3 and 0.5 (percent explained variance
between9–25%)moderate;between0.5and0.7(percentexplainedvariancebetween
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A total of 60 PD patientswere included in this study; 43men (72%) and 17women
(28%). Because of movement artifacts, the MR images of 5 PD patients had to be
excludedfromtheanalysis,sotheremainingsamplesizewas55PDpatients.Noneof
thepatientshadaclinicaldiagnosisofPDdementia.Baselinecharacteristicsareshown
in Table 1 and indicate that PD patients included had mild to moderate PD motor
symptoms and no clinically significantmood disorders. A fair percentage of patients
scoredabovethecutoffforclinicallyrelevantapatheticsymptoms:16.4%ontheLARS
(cutoff score 16/17),12.7%on theAES (cutoff score37/38),and32.7%on theNPI
(frequency * severity score 4 or higher). There were no associations between the
proportion of patients on levodopa or dopamine agonist and clinically relevant
apathetic symptomsasmeasuredwith the LARS,AES, andNPI (p=0.473,p=0.360,
p=0.584,p=0.211,p=0.640,andp=0.168,respectively).
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HAMD: Hamilton Depression Rating Scale; MMSE: Mini Mental State Examination; CAMCOG: Cambridge
Cognitive Examination; DA: dopamine; LARS: Lille Apathy Rating Scale; AES: Apathy Evaluation Scale; NPI:
NeuropsychiatricInventory





score and disease duration or the UPDRS part 3 total score. Scores on the AES
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HAMD     0.17 0.06 0.36* 0.55* 0.49*
MMSE      0.75* 0.42* 0.32* 0.06
CAM
COG
      0.49* 0.31* 0.17
LARS        0.83* 0.64*
AES         0.68*
NPI         
* Value is significant at P<0.05 (twotailed). UPDRS: Unified Parkinson’s Disease Rating Scale; HAMD:
HamiltonDepression Rating Scale;MMSE:MiniMental State Examination; CAMCOG: Cambridge Cognitive
Examination;LARS:LilleApathyRatingScale;AES:ApathyEvaluationScale;NPI:NeuropsychiatricInventory
Voxelbasedmultipleregressionanalysis
As shown in Table 3, the voxelbasedmultiple regression analysis showed significant
correlationsbetweengreymatterdensityvaluesandapathyscoresontheLARS,AES,
andNPI.HighapathyscoresontheLARScorrelatedwithlowgreymatterdensityvalues




multiple regression models, no correlations between these subscales and low grey
matterdensityvaluesindistinctanatomicalregionsotherthanthosementionedabove
wereobserved.HighapathyscoresontheAEScorrelatedsignificantlywithgreymatter
density values in the left precentral gyrus, thebilateral insula, thebilateral   inferior
frontalgyrus, the left inferiorparietalgyrus,andtheright (posterior)cingulategyrus.
Highapathy scoreson theNPI correlated significantlywith lowgreymatter  density
values in the left precentral gyrus, the bilateral insula, the bilateral inferior frontal
gyrus,theleftinferiorparietalgyrus,andtheright(posterior)cingulategyrus.
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Table3. Brainregionsshowingasignificant(negative)correlationbetweengreymatterdensityvalues
  andapathyscores








































































Inferiorparietalgyrus 3004 L 40 443339 4.75
Posteriorcingulategyrus 2807 R 31 175327 3.65























Inferiorparietalgyrus 2464 L 40 443339 4.49













16.4% on the LARS, 12.7%on theAES, and 32.7% on theNPI. In linewith previous
studies 5, 710, we found an association between apathy and cognitive dysfunction:
higher apathy scoreswere correlatedwith lowerMMSEandCAMCOGscores.Higher
apathy scores also correlated with higher depression scores, as measured with the
HAMD.Our studyconfirmsprevious findings showingnoassociationbetweenapathy
and severity of motor symptoms or disease duration 5, 810, although one recent
communitybased study of Pederson et al. (2008) did show a relationship between
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scales (LARS, AES, and NPI) in separate regressionmodels, which showed consistent
results.ThefourdifferentsubscalesoftheLARS(intellectualcuriosity,actioninitiation,
emotion, and self awareness)were also analyzed in separate regressionmodels. The
results showednocorrelationsbetween thesesubscalesand lowgreymatterdensity




the bilateral posterior cingulate gyrus 14. Isella et al. (2002) did not find any specific
measure of frontotemporal atrophy that correlatedwith severity of apathy 5. In this
particularstudythatcouldbeduetosmallsamplesizeorlackofsensitivityoraccuracy
ofthemorphometriclineartechniqueused.
Functional and structural neuroimaging studies addressing apathy in Alzheimer’s
disease (AD) showed that apathy is associated with grey matter density loss in the
(anterior)cingulateandtheinferiorfrontalgyrus3035.Apathologicalstudyofapathyin
ADalsoshowedafaircorrelationbetweenmoresevereapathyandanincreasedpatho
logicalburden in theanterior cingulategyrus 36. Lavretskyetal. (2007)examined the





apathy in PDaswell. This stresses the stability of neural substrates of apathy across
differentpathologies.
Ourresultsalsoshowedassociationsbetweenmoresevereapathyandlowgreymatter
density inotherareas: thepremotor cortex, thebilateral insula, the rightprecuneus,
and the bilateral inferior parietal gyrus. As the premotor cortex is involved in the
initiation of voluntarymovements, one could speculate that the greymatter density
lossinthisareamayresultinlessinitiativeandmotivationtoinitiatemovementsinPD
patientswith apathetic symptoms. As the insula plays a role in subjective emotional
experience,greymatterdensitylossinthisareamayberelatedtolossofspontaneous
emotion or emotional responsiveness, which is one of the characteristics of
apathy38, 39.Theparietal lobeplaysanimportantrole in integrating informationfrom
differentsensesandprocesses.Kjaeretal.(2002)hypothesizedthattheprecuneus,the
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inferior parietal gyrus, and the anterior cingulate gyrus constitute a functional network 
of  reflective  self‐awareness  40,  41.  This  network  has  previously  been  described  to  be 
impaired  in  apathy,  although  nowadays  there  is  still  a  debate  whether  this  is  a          
dimension  of  apathy  2.  In  addition,  the  inferior  parietal  gyrus  has  been  linked  to       
executive dysfunction  in PD when assessed with the Frontal Assessment Battery 42, 43. 
As  apathy  is  associated  with  executive  dysfunction  44,  one  could  hypothesize  that         
executive dysfunction in apathetic PD patients is not only linked to frontal lobe dysfunc‐
tion but also to parietal lobe dysfunction. 
Levy  and  Dubois  (2006)  hypothesize  that  apathy  can  be  described  as  the  clinical       
consequence  of  disruption  of  the  prefrontal‐basal  ganglia  system.  They  differentiate 
three  subtypes  of  disrupted  processing:  emotional‐affective,  cognitive,  and  auto‐
activation.  Involvement of  the cingulate gyrus and premotor cortex, as was shown  in 
our  study,  indicates  that  auto‐activation processing deficits  could be  associated with 
apathy in PD 12. 
Little  is known about the neurochemical mechanisms of apathy  in PD. A PET study of 
Remy  et  al.  (2005)  showed  that  the  severity  of  apathy  in  PD  patients was  inversely  
correlated  with  11C‐RTI‐32  binding  (dopamine  and  noradrenaline)  bilaterally  in  the  
ventral  striatum  13.  Czernecki  et  al.  (2002)  showed  that  levodopa  treatment might  
improve motivation  in some patients with PD,  indicating  that apathy  in PD  is at  least   
partly  a  dopamine‐dependent  syndrome  45,  46.  Dujardin  et  al.  (2007)  suggested  that 
nondopaminergic  circuits participate  in  the pathophysiology of apathy  in PD because 
the apathy  level  is mainly determined by cognitive  impairment and not by association 
with the severity of motor symptoms. PD‐specific pathology with multiple transmitter 




small cerebral areas  that are associated with apathy  in addition  to  those detected  in 
this study. Second, patients included in this study are characterized by only mild apathy 




of  apathy  in  PD.  This was  done  because  of  the  small  sample  size,  the mild  apathy 
scores,  and  the  lack of  consensus diagnostic  criteria  for  apathy  at  the  time of  study 
inclusion. Finally,  the VBM method used  to analyze our MRI data has been  criticized 
because  of  the  risk  of  misregistration,  caused  by  the  spatial  normalization                 
procedure  47,  48.  In  our  study,  registration  accuracy was  enhanced  by  alignment  and 
scaling with an advanced  registration method,  spreading  the  registration bias among 
the whole group  28,  29,  49. VBM has  the major advantage of analyzing  the whole brain 
and not be restricted by a priori assumptions about regions of interest. 
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evidence for involvement of the cingulate gyrus and the inferior frontal gyrus in the
pathophysiology of apathy in PD. Our results will have to be confirmed by future
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hypokineticrigid, tremordominant and postural instabilitygait difficulty 13. Our goal
wastoestablishsubgroupsbasedonthefullspectrumofclinicalsymptoms, including
both motor and psychopathological symptoms. We were able to identify four sub
groupsofPDpatients:agroupwithrapiddiseaseprogression,ayoungonsetgroup,a
nontremordominantgroupandatremordominantgroup.Thenontremordominant
subgroup was also characterized by cognitive deterioration, more severe depressive
and apathetic symptoms, and more severe hallucinations (Chapter 4). Lewis et al.
(2005)also investigatedtheheterogeneityofPD.Theirstudyshowedfoursubgroups,
comparabletotheoneswefound;arapiddiseaseprogression,ayoungdiseaseonset,a
tremordominant and a nontremordominant with significant levels of cognitive
impairmentandmilddepression4.
Anote thathas tobemade is that thediscriminationof subgroupsdescribedabove,
partlyrepresentsadiscriminationoftimeofdiagnosis,whileotherdiscriminationscan
onlybemadeafteranumberofyearsofdiseaseprogression.Thisalso indicatesthat
patients assigned to a certain subgroup at a certain time point, can be assigned to
anothersubgroupastimeanddiseaseprogresses.
With the goal to confirm the classification of Lewis et al. (2005), a recent study of
Selikhovaet al. reviewed242donorswithpathologically verifiedPD from theQueen
Square Brain Bank for Neurological Disorders. Cases were segregated into the four




different clinical subgroupsmay have different pathological processes which in turn
may have different aetiological bases. If this is indeed the case, this has important
implications forclinicalcareand future research.Defining subgroupsofpatientswith
PD will then be useful in delineating the prognosis and therapeutic options.
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patients with PD: depression and apathy. One diagnostic  issue  is  the  recognition and 
assessment of depression  in PD patients. The systematic review of prevalence studies 
of depression in PD (Chapter 2) showed weighted prevalence rates for major depressive 
disorder,  minor  depression,  and  dysthymia  of  17%,  22%,  and  13%,  respectively.       
Clinically significant depressive symptoms are present in 35% of PD patients, indicating 
that depressive symptoms are common in PD patients. In contrast, prevalence rates of  
major  depressive  disorder  based  on  standardized  diagnostic  criteria  (Diagnostic  and 




workgroup  from the National  Institute  for Neurological Diseases and Stroke 7 and the 
National  Institute of Mental Health 7 has therefore  issued the following recommenda‐
tions: (1) an inclusive approach to symptom assessment to enhance reliability of ratings 
in  PD  and  avoid  the  need  to  attribute  symptoms;  (2)  anhedonia  should  only  be        
diagnosed based on  loss of pleasure  rather  than  loss of  interest  (as  it overlaps with 
apathy) for diagnosis of minor depression/subsyndromal depression, (3) elimination of 
the DSM exclusion criteria  ‘due  to  the effects of a general medical condition’,  (4)  the 
inclusion of subsyndromal depression  in clinical research studies;  (5)  the specification 
of  timing  of  assessments  for  PD  patients  with  motor  fluctuations  and  the  use  of       
informants for cognitively impaired patients 7. 
Nevertheless, the contribution of somatic items to the diagnosis of depression in PD is 
still  an  issue  of  debate.  We  addressed  this  issue  by  investigating  the  influence  of      
excluding  somatic  items  from  two  depression  rating  scales  on  the  clinimetric            
performance. The results (Chapter 3) showed that elimination of somatic items lead to 
a  reduced  specificity  and  unchanged  sensitivity  for  the  Hamilton  Depression  Rating 
Scale (HAMD) 8 and a reduced specificity and increased sensitivity for the Montgomery‐
Åsberg Depression Rating Scale (MADRS) 9. We therefore recommend the full versions 
of  the  two scales  if used  for diagnostic purposes, with adjusted cut‐off scores  for PD 
patients. For screening purposes, the abbreviated version without somatic items can be 
used.  However,  generally  self  report  scales  are  preferred  for  screening.  Additional  
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Another diagnostic issue in diagnosing depression in PD is the considerable overlap
betweendepressionandapathy.Depressivepatientsoftenhavesymptomsofapathy;
however apathy can occur in the absence of depression 1012. In our validation study
(Chapter5),17.2%of the includedPDpatientsmet thediagnosticcriteria forapathy,
whereas5.7%hadbothmajordepressivedisorderandapathy.Thereportedprevalence
ofapathy is low,whichcouldbeduetothefactthatonlynondementedPDpatients
were included, whereas the frequency of apathy is higher in patientswith cognitive




It is yet unclear whether separate neural systems underlie depression and apathy.
Depression in PD has been associated with grey matter decrease in the bilateral
orbitofrontal, right temporal regions, and the limbic system 15. In Chapter 6, we
addressedtheneuroanatomicalcorrelateofapathyinPD,showingtheinvolvementof
the cingulate gyrus and inferior frontal gyrus. It could be hypothesized that





our studies, patients with idiopathic PD fulfilling the clinical criteria of the Queen
Square Brain Bank were included 18. We did not perform an additional diagnostic
assessment with, for instance, IBZM or CIT single positron emission tomography
(SPECT) in order to verify the diagnosis. This implies that some people may be
incorrectly diagnosedwithPD,whereas in fact theymay suffer fromother causesof




patients. The other recommendations of the NINDS/NIMH workgroup, described
earlier,werealsofollowed7.
In 2008, a consensus meeting was held between the Association Française de
PsychiatrieBiologique(AFPB),theEuropeanPsychiatricAssociation(EPA),theEuropean
Alzheimer’s Disease Consortium (EADC), and invited experts from Europe, Australia,
and North America, to propose consensus diagnostic criteria for apathy as a
syndrome 20 (see Appendix). These proposed diagnostic criteria have subsequently
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been validated  in 306 patients suffering  from a range of neuropsychiatric diseases.  In 
this  study,  the  criteria were  shown  to have  good  acceptability,  inter‐rater  reliability, 
and known‐groups validity 21. A validation study of these criteria in a population of PD 




In  all  studies  presented  in  this  thesis,  rating  scales  were  used,  besides  diagnostic     
criteria,  to  asses  psychopathology  and motor  symptoms  in  PD  (see  Appendix).  For  
assessment  of  depression,  the HAMD  and  the MADRS were  used.  Both  scales were 
reviewed by  the Movement Disorder Society  (MDS)  task  force and  recommended  for 
screening and assessment of severity of depression in PD 22. 
In  Chapter  6,  apathy was  assessed with  the  Lars  Apathy  Rating  Scale  (LARS)  23,  the   




of  patients  with  clinically  relevant  apathetic  symptoms, measured  with  the  NPI,  in   
comparison  to  the  LARS  and AES. On  the other hand, a  study of Kinlay et  al.  (2008) 
reported lower frequencies of apathy based on caregiver reports in comparison to self‐
report  26.  Therefore,  caution  is  needed  when  comparing  frequencies  of  neuro‐
psychiatric symptoms derived from self‐reports and caregiver‐reports. 
To quantify motor  symptoms of PD, we used  the Unified Parkinson’s Disease Rating 
Scale  (UPDRS)  27.  This  is  the most  frequently  used  and most  thoroughly  studied  PD 
rating  scale,  with  a  good  internal  consistency,  inter‐rater  reliability  and  criterion      
validity  28.  In  Chapter  4, we  also  used  items  from  the UPDRS mood  and mentation   
section  (section  1)  to  quantify  psychopathological  symptoms.  The  UPDRS  has  very  
recently been revised  into a partly observer‐ and partly self‐rated scale, named MDS‐
UPDRS 29. The first section addressing non‐motor symptoms has expanded from 4 to 13 
items,  stressing  the  importance of  these  symptoms  in PD. For assessment of depres‐
sion,  the new version will  focus only on mood  to avoid ambiguities and overlap with 
symptoms  of  PD.  Some  of  the  somatic  features  of  depression,  as  well  as  apathy,      
cognitive  impairment,  anxiety,  and  sleep  disturbances, will  be  assessed  in  separate         
questions. The new version of the UPDRS should be used as a screening instrument for 
non‐motor  symptoms,  an  accompanying  appendix  will  provide  ‘recommended’  and 
‘suggested’ scales for further evaluations. 
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one from an outpatient based study ofMaastricht UniversityMedical Centre. In the
validation study described in Chapter 5, an outpatient study sample from Lille






mean age of the participants, this approach might have caused a selection bias.
Although it must be stressed that these patients were recruited from various
departments.
Statisticalmethodsused
Our statistical analysis included ‘ordinary’ descriptive statistics, chisquare tests
(Chapters 2, 5), correlational statistics (Chapters 5, 6) and classification analysis








ground.Amajor strengthofour study is thatnotonlyanexplorativeclusteranalysis
wasdonebutalsoaconfirmativeanalysisbywhichclassificationaccuracyisproven.
In Chapter 6, VBM was used as an analyzing technique to examine the association
betweenapathyandgreymatterdensityinPDpatients.Oneofthemajoradvantages
of thismethod is that thewhole brain is analyzed at once, in contrasts to region of
interest (ROI) approaches. This is especially relevant when there are no apriori
assumptions of specific brain areas of interest, which was the case in our study of
anatomical (grey matter density) correlate of apathy in PD. Although the structural




MOOD & MOT IVAT ION  I N  P ARK INSON ’ S  D I S EAS E 
be confirmedwith studiesusingROI approaches, analyzingmethodswhicharemuch
moretimeconsuming.
7.3 Clinicalimplications
Our findings have several clinical implications. Our cluster analysis, described in
Chapter 4, showed that psychopathological symptoms (depression, apathy, cognitive
deterioration, and hallucinations) all cluster together in one specific subgroup of PD
patients.Thisfindinghastwoimportantimplications.
First,screeningforpsychopathologyinPDpatientsbelongingtothisspecificsubgroup.
Physicians shouldbemoreawareand screenmore frequently forpsychopathological
symptoms when encountering patients with nontremordominant motor symptoms
like hypokinesia, rigidity, postural instability, and gait disorder. Related to this, there
are known risk factors associated with specific psychopathological symptoms. For
depression, family history of depression and rightsided onset of symptoms are risk
factors30.Forapathy,independentriskfactorsaredementiaandamorerapiddecline
inspeechandaxial impairment31.Physicianshouldbeawareof theserisk factors, to
enhanceearlyrecognitionofpsychopathologicalsymptoms.
Second, the treatmentstrategiesapplied toapatientare influencedby thesubgroup
the patient belongs to. Patients from the nontremordominant subgroup are
characterized by more severe psychopathological symptoms like depression and
apathy. Many of these patients will already be on dopaminergic medication and/or
require improvement ofmotor symptoms. The first stepwhen encountering psycho
pathological symptoms would therefore be the optimization of existing treatment.
SomedopaminergicagentsthatareusedtotreatthemotorsymptomsofPDhavebeen
advocatedtohaveadditionalpositiveeffectsonmood,anhedonia,andmotivation3235.




also be argued that screening for a specific symptom should be dependent on the
availability of treatment options. For example screening for cognitive impairment is
important because pharmacological treatment options, in case of PDdementia, are
moreeffectiveinearlystagesthaninlaterstages,whenthepatientwouldhavenoticed
the symptomshimself. Screening for depressionmight alsobeuseful becauseof the




of depression, it is important to adopt the recommendations from theNINDS/NIMH
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workgroupdescribedearlier,likeadoptingainclusiveapproach,eliminationoftheDSM
exclusion criteria ‘due to the effects of a general medical condition’ and diagnosing
anhedoniabasedonlossofpleasureratherthanlossofinterest7.
Another diagnostic issue is the overlap between depression and apathy. It may be
difficulttodistinguishdepressionfromapathywhenseeingapatient(orcaregiver)who
reports apathetic symptoms. The proposed diagnostic criteria, with good concurrent
and fair discriminant validity, are therefore very important. It provides a diagnostic
instrumentthathelpsphysicianstoestablishanaccuratediagnosis.
Hopefully by addressing some of the diagnostic issues concerning depression and
apathy in this thesis, the early recognition and diagnostic accuracy of these stressful
symptomswill increase.Two lastconditions,whichareessential forearly recognition
and accurate diagnosis, are a close collaboration between neurologists and
psychiatristsandanopeninteractionbetweenpatient/caregiverandtheirphysicianin
which thepatient/caregiver feels free to talk about theproblems theyencounters in
theireverydaylife.
7.4 Furtherresearch
Based on the findings in the present thesis, some recommendations for further
researchcanbeformulated.TheidentificationofthedifferentsubgroupsofPDpatients
can be an important basis of further research. Functional imaging techniques, like
positronemission tomography (PET) and functionalMRI (fMRI), shouldbe applied to
these subgroups to reveal different aetiopathologies. We could hypothesize that a
differentconstellationofneurotransmittersystemsare involvedintheetiologyofthe
four subgroups. This can be investigated by using PET or SPECT imaging. If the
involvementofvariousneurotransmittersystems is indeeddifferent for the foursub
groups, this could have important therapeutic possibilities. Nevertheless, further
prospectiveresearchwithlongitudinalassessmentofpatientsisneededtodistinguish






clear relation between greymatter atrophy in a number of cortical brain areas and
symptoms of apathy. But understanding of the underlying neural networks is still
lacking. Future research should try to gainmore insight in these neural networks by
combiningstructuralwithfunctionalimagingtechniques.Besidesthis,inourstudyonly
nondemented PD patients were included. New studies should investigate the
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limited and inconsistent evidence for the efficacy of any specific drug in treating
apathy, although cholinesterase inhibitors and methylphenidate may be the best
candidates for future randomized controlled trials 38. Also nonpharmacological
treatment options should be addressed in future studies. Hopefully this will lead to
effective treatment options which will improve quality of life for both patient and
caregiver.
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 markedly diminished interest or pleasure in all, or nearly all, activities
most of the day, nearly every day (as indicated by either subjective
accountorobservationmadebyothers)












C. The symptoms cause clinically significant distress or impairment in social,
occupational,orotherimportantareasoffunctioning.




E. Thesymptomsarenotbetteraccounted forby ‘bereavement’, i.e.,after the
lossofalovedone.
DSMIVTRcriteriaforDysthymicdisorder3
















of functioning and which is not consistent with his age or culture. These
changes in motivation may be reported by the patient himself or by the
observationsofothers.






 Initiation symptom: loss of selfinitiated behaviour (for example:
starting conversation, doingbasic tasks ofdaytoday living, seeking
socialactivities,communicatingchoices).
 Responsivenesssymptom: lossofenvironmentstimulatedbehaviour
(for example: responding to conversation, participating in social
activities).
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 Initiation symptom: loss of spontaneous ideas and curiosity for
routine, and new events (i.e., challenging tasks, recent news, social
opportunities,personal/family,andsocialaffairs).
 Responsiveness symptom: lossof environmentstimulated ideas and





 Initiation symptom: loss of spontaneous emotion, observed or self
reported(forexample,subjectivefeelingofweakorabsentemotions,
orobservationbyothersofabluntedaffect).





C. These symptoms (A  B) cause clinically significant impairment in personal,
social,occupational,orotherimportantareasoffunctioning.
D. The symptoms (A  B) are not exclusively explained or due to physical
disabilities (e.g., blindness and loss of hearing), to motor disabilities, to
diminished level of consciousness or to the direct physiological effects of a
substance(e.g.,drugofabuse,amedication).
UnifiedParkinson’sDiseaseRatingScale(UPDRS)5























The interviewerrated HAMD is the most widely used and accepted measure for
evaluatingtheseverityofdepression.Itsuseasascreeningmeasurehasbeencritized
andsomatic itemsareheavily represented.Although itcoversDSMIVcriteria incom




The MADRS is an observerrated scale. It covers all the DSMIV criteria of a major
depressive episode, with the exception of psychomotor retardation/agitation and
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NeuropsychiatricInventory(NPI)9,10
TheNPIwasdevelopedasastructured interviewconductedbythecliniciantoassess
10 forms of behavioural disorder that occur in patients with dementia, including
delusions, hallucinations, agitation/aggression, depression, anxiety, euphoria, apathy,
disinhibition,irritability,andaberrantmotorbehaviour.Subsequentlya12itemversion
wasdevelopedthatalsoincludedsleepandappetitedisturbances.Allitemsconsistofa





higher scores indicating higher levels of apathy. The 18 items include four self
evaluation items that are scored exclusively on the patient’s rating and one item










impaired patients. It is a simple and universally applied scale that can be easily and
rapidly performed by a clinician. It exists of a number of short questions and tasks,







subdimensions, each covering a specific cognitive domain: orientation, language
(comprehension and expression), memory (recent, remote, and new learning),
attention, praxis, abstract thinking, and perception. Total scores range between 0























10. Cummings JL,MegaM, Gray K, RosenbergThompson S, Carusi DA, Gornbein J. The Neuropsychiatric
































PD is the most common movement disorder and the second most common neuro
degenerative disorder after Alzheimer’s disease. Psychopathological symptoms are
common in PD and significantly contribute to disability, reduced quality of life, and
caregiverdistress.Thefirstaimofthisthesisistoidentifypatientsubgroupsbasedon













In Chapter 2, a systematic review of prevalence studies of depression in PD is







cantdepressive symptoms, irrespectiveof thepresenceofaDSMdefineddepressive
disorder, were present in 35%. In studies using a (semi) structured interview to
establishDSMcriteria,thereportedprevalenceofmajordepressivedisorderwas19%,
while in studies using DSM criteria without a structured interview, the reported
prevalence of major depressive disorder was 7%. Population studies report lower
prevalence rates for both major depressive disorder and the clinically significant




In Chapter 3, a study to assess the influence of somatic symptoms of the Hamilton
Depression Rating Scale (HAMD) and MontgomeryÅsberg Depression Rating Scale
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the HAMD and MADRS. Sensitivity, specificity, positive, and negative predictive values 
for a  range of  cut‐off  scores were  calculated  for both  rating  scales and  for modified 
versions of these scales in which all somatic items were eliminated. In addition, receiver 
operating  characteristic  curves were obtained  for both  the modified and unmodified 
scales. The results showed that elimination of the somatic items of depression from the 
HAMD and MADRS resulted in a reduced specificity of both the HAMD and the MADRS, 
and  an  increased  sensitivity  of  the MADRS. We  recommend  the  full  version  of  the 





In  Chapter  4,  a  cluster  analysis  study  is  described  to  investigate  the  association        
between motor subtypes and psychopathology in PD. An exploratory and confirmatory 
cluster  analysis  of  motor  and  psychopathological  symptoms  was  performed  with  a 
randomized sample of 173 patients each, stemming from two research databases: one 
from Stavanger University Hospital and one from Maastricht University Hospital. These 
databases  contained  data  of  standardized  assessments  of  patients with  the  Unified 
Parkinson’s Disease Rating Scale, the Montgomery‐Åsberg Depression Rating Scale, and 
the  Mini  Mental  State  Examination.  The  results  showed  that  PD  patients  can  be        
accurately and reliably classified into four different subtypes: rapid disease progression 
subtype,  young‐onset  subtype,  non‐tremor‐dominant  subtype with  psychopathology, 
and  a  tremor‐dominant  subtype.  Cognitive  deterioration,  depressive  and  apathetic 
symptoms,  and  hallucinations  all  cluster  within  the  non‐tremor‐dominant  motor     




described.  In  a  cross‐sectional  study,  PD  outpatients  visiting  a movement  disorders 
clinic underwent a protocolized assessment of motor function, activities of daily living, 
cognition, and mood. In addition, the diagnostic criteria for apathy were administered 
as well  as  two  apathy  rating  instruments:  Lille  Apathy  Rating  Scale  (LARS)  and  the    
apathy section of the Neuropsychiatric Inventory (NPI). The results showed that 17.2% 





behaviour was most  frequently  observed. We  concluded  that  the  recently  proposed 




diagnostic criteria for apathy are useful in clinical practice and in research with PD
patientswithandwithoutcognitiveimpairment.

In Chapter 6, a structural imaging study to determine the correlates of apathy in PD
patients is described. Sixty PD patients underwent a neuropsychiatric and neuropsy
chologicalexamination,anda3teslamagneticresonanceimagingscanwasacquired.A





the bilateral inferior parietal gyrus, the bilateral inferior frontal gyrus, the bilateral
insula,theright(posterior)cingulategyrusandtherightprecuneus.Weconcludedthat
involvementofthecingulategyrusandinferiorfrontalgyrusisinlinewiththeresultsof
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Het eerste doel van het onderzoek beschreven in dit proefschrift is het identificeren
vansubgroepenvanpatiëntengebaseerdopzowelmotorischealspsychopathologische
symptomen.Hettweededoelishetbehandelenvanenkelediagnostischevraagstukken
















prevalenties van depressieve stoornissen bij de ZvP te berekenen, waarbij rekening
wordt gehouden met verschillende settings en verschillende diagnostische
benaderingendiegebruiktworden indegeïncludeerde studies. In totaalwerden104
artikelen geïncludeerd en beoordeeld op kwaliteit aan de hand van vastgestelde
kwaliteitscriteria;51artikelenvoldedenaandekwaliteitscriteria.Publicatiesgebaseerd
op dezelfde onderzoekspopulatie werden vervolgens geëxcludeerd waardoor er 36
artikelenuiteindelijkwerdenmeegenomenindeanalyses.Degewogenprevalentievan
een ‘depressieve stoornis’, een ‘subklinische depressie’ en een dysthyme stoornis
warenrespectievelijk17%,22%en13%.Klinischsignificantedepressievesymptomen,
ongeacht de aanwezigheid van een diagnose ‘depressieve stoornis’ volgens de DSM
criteria, waren aanwezig in 35% van de parkinson patiënten. In studies die gebruik
maakten van een (semi) gestructureerd interview om een DSM diagnose vast te
stellen,wasdeprevalentievaneendepressievestoornis19%,terwijlinstudiesdiegeen
gebruikmaaktenvaneengestructureerdinterview,deprevalentievaneendepressieve
stoornis 7%was. Bevolkingsstudies rapporteerden een lagere prevalentie voor zowel
eendepressieve stoornis als klinisch significantedepressieve symptomendan studies
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In  hoofdstuk  3  wordt  een  onderzoek  beschreven  naar  de  invloed  van  somatische   
symptomen  van  de  Hamilton  Depression  Rating  Scale  (HAMD)  en  de Montgomery‐
Åsberg Depression Rating Scale (MADRS) op de klinimetrische eigenschappen van deze 
schalen bij patiënten met de  ZvP.  In  totaal ondergingen 224 patiënten  een  geproto‐
colleerd mentale status onderzoek, bestaande uit een gestructureerd klinisch interview 
om de DSM  IV  criteria voor een depressieve  stoornis  te kunnen vaststellen  (SCID‐D). 
Tevens werden de HAMD en de MADRS afgenomen. Sensitiviteit, specificiteit, positief 
en negatief voorspellende waarden werden berekend voor een reeks van afkappunten, 
voor  zowel  de  gewone  depressieschalen  als  voor  een  aangepaste  versie  van  deze    
depressieschalen  waarbij  alle  somatische  items  werden  geëlimineerd.  Ook  werden 
‘receiver  operating  characteristic’  curven  berekend  voor  zowel  de  gewone  als  de     
aangepaste  depressieschalen.  De  resultaten  lieten  zien  dat  eliminatie  van  de            
somatische items van de HAMD en MADRS,  resulteerde in een afgenomen specificiteit 
van  zowel de HAMD als de MADRS, en een  toegenomen  sensitiviteit van de MADRS. 
Onze aanbeveling  is het gebruik van de originele versies van de HAMD en de MADRS, 
voor  diagnostische  doeleinden.  Als  screeningsinstrument  kunnen  de  aangepaste     
versies,  zonder  somatische  items,  worden  gebruikt.  Bijkomende  voordelen  van  het 
gebruik van de originele versies, met somatische  items, zijn dat deze meer  informatie 











Examination.  De  resultaten  toonden  aan  dat  patiënten met  de  ZvP  nauwkeurig  en  
betrouwbaar  kunnen  worden  ingedeeld  in  vier  verschillende  subtypes:  een  ‘young‐
onset’  subtype,  een  ‘rapid  disease  progression’  subtype,  een  ‘tremor‐dominant’      
subtype en een ‘non‐tremor‐dominant’ subtype met psychopathologische symptomen. 
Cognitieve  achteruitgang, depressieve  symptomen,  apathie en hallucinaties  clusteren 





In  hoofdstuk  5 wordt  een  validatiestudie  van  de  voorgestelde  diagnostische  criteria 
voor  apathie  bij  de  ZvP  beschreven.  In  een  cross‐sectionele  studie,  bezochten  poli‐
klinische  patiënten met  de  ZvP  een  bewegingsstoornissen  poli  en  ondergingen  een 














In  hoofdstuk  6  wordt  een  structureel  beeldvormingonderzoek  naar  de  neurale         
correlaten van apathie bij patiënten met de ZvP beschreven. Zestig patiënten onder‐
gingen een neuropsychiatrisch en neuropsychologisch onderzoek. Tevens werd een 3 
tesla  MRI‐scan  van  het  brein  gemaakt.  Vervolgens  werd  een  voxel‐based  regressie  
analyse  gebruikt  om  de  relatie  te  onderzoeken  tussen  de  ernst  van  de  apathische  
symptomen  en  veranderingen  van  grijze  stof  volume.  De  resultaten  lieten  zien  dat  
apathie correleerde met een verminderd cognitief  functioneren en meer depressieve 
symptomen, maar  niet met  de  ernst  van  de motorische  symptomen.  Hoge  apathie 
scores  correleerde  met  een  verminderd  grijze  stof  volume  in  een  aantal  corticale    
hersengebieden: de bilaterale precentrale gyrus, de bilaterale inferieur parietale gyrus, 
de  bilaterale  inferieur  frontale  gyrus,  de  bilaterale  insula,  de  rechter  (posterior)       
cingulate gyrus en de rechter precuneus. We concludeerden dat de betrokkenheid van 




In  hoofdstuk  7 worden  de  resultaten,  beschreven  in  dit  proefschrift,  nogmaals  kort 
besproken  aan  de  hand  van  de  gestelde  onderzoeksdoelen.  Daarnaast  worden        





















de afgelopen  jaren. Zonder  jullie  inzet en motivatie had dit proefschrift niet tot stand 





klinisch  onderzoek  te  doen  en  voor  het  vertrouwen  in mij.  Veel  dank  voor  je  inzet,  






hulp  bij  de  inclusie  van  patiënten  en  bij  de  uitvoering  van mijn  onderzoek,  in  het     





onderzoek.  Elissa,  fijn  dat  je me  zo  nu  en  dan  uit  de  brand  wilde  helpen  en mijn       
scanbuddy wilde zijn. Pauline, bedankt voor je betrokkenheid en, Jeroen, voor al je hulp 
bij het scannen en het analyseren van de VBM‐data. Richel, bedankt voor je statistische 
hulp  bij  een  aantal  artikelen  in  dit  proefschrift  maar  bovenal  voor  je  persoonlijke    
betrokkenheid en adviezen die ik niet snel zal vergeten! 
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ontspannende maandagavonden. Jozien, bedankt voor je vertrouwen; je bent mijn
inspiratiebron.

Lieve vrienden en vriendinnen, dankjewel voor onze bijzondere vriendschappen. Ik





































MOOD & MOT IVAT ION  I N  P ARK INSON ’ S  D I S EAS E 
 140
CURR I CU LUM  V I T EA  
1980    Born on September 10th 1980, Heerlen, the Netherlands. 
1993 – 1997  Higher  General  Secondary  Education,  Scholengemeenschap  Sancta 
Maria, Kerkrade, the Netherlands. 
1997 – 1998  Pre‐university Education, Stercollege, Maastricht, the Netherlands. 








2005    Research‐assistant  at  the  Department  of  Neurology  of  the  Bakken 
Research  Centre  Maastricht  (Medtronic),  the  Netherlands.  
Project:  “Evaluation  of  the  effectiveness  of  neurostimulation  in      
Parkinson’s disease”. 
2005 – 2006  Clinical  traineeship  at  the  Department  of  Neuropsychiatry  of  the  
Psycho‐medical  Institute  (PMS)  Vijverdal  (Mondriaan  Zorggroep), 
Maastricht, the Netherlands. 
2006 – 2007  Research‐associate  at  the  Department  of  Psychiatry  and  Neuro‐
psychology, Faculty of Health, Medicine and Life Sciences, Maastricht 
University, Maastricht, the Netherlands.  
2007 – 2010  PhD‐student at  the Department of Psychiatry  and Neuropsychology, 
Faculty of Health, Medicine and Life Sciences, Maastricht University, 
Maastricht, the Netherlands.  
    Project:  “Apathy  in  patients  with  Parkinson’s  disease,  a  structural 
brain imaging study using voxel based morphometry”. 
2010 – Present  Post‐doctoral researcher at the Department of Psychiatry and Neuro‐
psychology,  Maastricht  University  Medical  Centre,  Maastricht,  the 
Netherlands. 
  141 






MOOD & MOT IVAT ION  I N  P ARK INSON ’ S  D I S EAS E 
 144





 Reijnders JSAM, Ehrt U, Lousberg R, Aarsland D, Leentjens AFG. The
association between motor subtypes and psychopathology in Parkinson’s
disease.Parkinsonism&RelatedDisorders2009;15:379382(Chapter4).

 Reijnders JSAM, Lousberg R, Leentjens AFG. Assessment of depression in




 Reijnders JSAM, Scholtissen B,WeberWEJ, Aalten P, Verhey FRJ, Leentjens
AFG.NeuroanatomicalcorrelatesofapathyinParkinson’sdisease:amagnetic




of diagnostic criteria for apathy in Parkinson’s disease. Accepted for
publicationinParkinsonism&RelatedDisorders(Chapter5).





 Reijnders JSAM, Schiphof F, Leentjens AFG. The validity of theMiniMental
State Examination in the detection of Parkinson’s disease Dementia
(inpreparation).

 145
